Hims & Hers Health Inc. (HIMS) stock plummeted 10.61% during Tuesday's intraday session, extending significant pre-market losses.

The sharp decline follows the company's release of mixed fourth-quarter 2025 financial results and disappointing forward guidance. While Hims & Hers beat earnings per share estimates, its quarterly revenue of $617.82 million fell short of analyst expectations. More critically, the company issued first-quarter 2026 revenue guidance in the range of $600 million to $625 million, substantially below the consensus estimate of $653.12 million, casting doubt on near-term growth prospects.

Investor sentiment was further weighed down by multiple analyst price target cuts and ongoing regulatory uncertainty. Several brokerages, including Citigroup, Truist Securities, and BofA, downgraded their targets following the report. The company faces significant scrutiny over its GLP-1 weight-loss business, including a lawsuit from Novo Nordisk and potential regulatory action from the FDA, which has been referred to the Department of Justice. Specific operational headwinds, such as a $65 million revenue impact from changes in shipping cadences for personalized prescriptions and pressure from a Super Bowl advertising investment, added to the negative outlook.